Which antipsychotic agent is available in a long-acting injectable formulation for patient adherence?

The agent that is available in a long-acting injectable formulation is aripiprazole. Long-acting injectable antipsychotics are beneficial for patient adherence as they reduce the frequency of medication administration and help ensure that patients maintain a consistent level of the medication in their system. Aripiprazole can be administered every month or once every three months, depending on the specific formulation, which supports adherence by minimizing the burden of daily medication.

This formulation is particularly important for patients with schizophrenia or bipolar disorder, as it can help mitigate the risk of relapse due to non-compliance with oral regimens. The convenience of long-acting injectables can greatly enhance treatment outcomes by providing more stable pharmacokinetics and reducing the peak-trough fluctuations associated with daily oral dosing.